Jennifer Burstein, MBA, CPA

Jennifer Burstein is a director of Stoke Therapeutics. She currently serves as the SVP Finance Operations of Treeline Biosciences, Inc., since March 2021. She served as senior vice president of finance and principal financial officer at Loxo Oncology, Inc., until its acquisition by Eli Lilly and Company in January 2019. From 2006 to 2015, Jennifer held roles of increasing responsibility in finance at Acorda Therapeutics, Inc., and ultimately served as vice president of finance for the company from 2010 to 2015. Before that, she worked on the finance team at Eyetech Pharmaceuticals, Inc., which is currently a subsidiary of Valeant Pharmaceuticals International, Inc. Earlier in her career, Jennifer worked in the finance departments at several companies and in public accounting. She holds a B.S. in business administration and her MBA in accounting, both from the State University of New York at Buffalo, and holds a CPA license in New York.